Moderate riskFDA DrugClass II

Major Pharmaceuticals levothyroxine tablets recalled for subpotency

Major Pharmaceuticals is recalling one lot of Levothyroxine Sodium Tablets, USP 125 mcg due to subpotency—meaning the tablets contain less active ingredient than expected. This affects lot #N02266 with an expiration date of 11/2026. The affected tablets were distributed nationwide.

From the FDA notice · Read the official notice ↗

What to do

  1. Check if you have levothyroxine from lot #N02266 (expiration 11/2026) by looking at your prescription bottle.
  2. Contact your pharmacy or doctor if you have this lot; do not stop taking your medication without medical guidance.
  3. Return the affected tablets to your pharmacy for disposal and replacement.

Is yours affected?

Compare your label or packaging with the recalled product.

Product
Levothyroxine Sodium Tablets, USP, 125 mcg (0.0125 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6955-61
Sold in
Nationwide
Made for
Adults (0 months and older)

This recall covers 12 products — see all of them.

Details

Units affected
N/A
Illnesses reported
None reported
Manufactured in
7000 Cardinal Pl, N/A, Dublin, OH, United States
Classification
Class II
Recall number
D-0705-2026

In the FDA's words

Description
Levothyroxine Sodium Tablets, USP, 125 mcg (0.0125 mg), 100 Tablets (10 x 10 unit dose blisters) per carton, Rx only, Packaged and Distributed by: MAJOR PHARMACEUTICALS, Indianapolis, IN 46268 USA. NDC: 0904-6955-61 Subpotent Drug Lot #: N02266, Exp. Date 11/2026 Distribution: Nationwide in the USA. Affected quantity: N/A
Hazard
Subpotent Drug

12 products in this recall

The agency lists each product separately. Check every one you might have.

Related topics

PotencyDrugsSold nationwideMore from FDA Drug